Testing a new tuberculosis vaccine in healthy adults
Part of Infections clinical trials.
This early-phase trial tests a new vaccine designed to prevent tuberculosis (TB). It helps researchers see if the vaccine is safe and produces an immune response in healthy adults. Participation may contribute to the development of a new prevention tool for TB.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 40 years old.
- You must be in generally good health and have normal blood and urine test results.
- You must have a negative test for TB infection (IGRA) and no TB bacteria in your sputum.
- You must not have had TB in the past or have ever been treated for TB (including latent TB).
- You must not have a chronic serious condition like diabetes, thyroid disease, or heart failure.
- You must not be pregnant, breastfeeding, or planning a pregnancy during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests MTBVAC, a TB vaccine candidate, to see if it is safe and whether it helps the immune system. It may be a fit if you’re eligible for TB and HIV-related vaccine safety testing and can follow study visits and testing.
This study measures how strongly your immune system responds to COVID-19 vaccines. It includes people with newly diagnosed tuberculosis and a healthier comparison group, aiming to understand vaccine immune effects and safety.
This trial tests an experimental vaccine called VIR-1778 that may help protect against infections caused by two viruses: cytomegalovirus (CMV) and tuberculosis (TB). The study looks at whether the vaccine is safe and how well it works in healthy adults.
This trial tests a new skin test (EEC) to see if it can accurately detect tuberculosis infection in people aged 3 and older. It compares the test's results in healthy people, people with TB, and people with other lung diseases to check how well it works.
This Phase 3 study tests whether MTBVAC can safely protect newborn babies from tuberculosis and whether it helps the baby’s immune system learn to fight TB. If you enroll, the goal is to see safety and immune response in real newborn settings in sub-Saharan Africa.
This study tests new, faster ways to detect tuberculosis (TB) using phlegm, tongue swabs, or urine. It aims to find a simpler and more accurate test than current ones, which could help you get the right treatment sooner.
Hear when a new Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.